ScripWhile regulatory uncertainty in the US is mounting, Amgen does not expect significant revenue impact from new tariffs implemented under US President Donald Trump, chief financial officer Peter Griffit
ScripA month after shelving its previous lead drug candidate, izokibep, Acelyrin said on 6 January that it is moving lonigutamab into Phase III in thyroid eye disease with a revised dosing regimen from Pha
ScripViridian unveiled successful across-the-board Phase III data on 16 December for veligrotug in chronic thyroid eye disease (TED), roughly three months after similar broad Phase III success with the can
ScripAnalysts at PwC expect dealmaking in the life sciences sector to pick up in 2025, but they predict more of the kind of dealmaking that the biopharma industry has favored in recent years, such as bolt-